Dezima Initiates Phase 2b TULIP Study on CETP Inhibitor Program DEZ-001

News   Aug 30, 2013

 
Dezima Initiates Phase 2b TULIP Study on CETP Inhibitor Program DEZ-001
 
 
 

RELATED ARTICLES

FoxO Proteins Implicated in Arthritis Age Risk

News

A study examining osteoarthritis has shown that as joints age, levels of FoxO decrease, causing pain and inflammation.

READ MORE

Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate Growth

News

Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.

READ MORE

New Technology Enables Identification of Biomarkers for a Wide Range of Diseases

News

Scientists have developed a way to identify biomarkers for a wide range of diseases by assessing the antibodies we are making to the complex sugars coating our cells.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE